Brought to you by 
Series A brings in $27mm for Aerpio Therapeutics; adds $9mm
08 Nov 2013
Executive Summary
Novartis BioVenture has led Aerpio Therapeutics Inc.’s (drug candidates for vascular and inflammation conditions) $27mm Series A venture round. Other participants included Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, and AgeChem Venture Fund.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings in $27mm for Aerpio Therapeutics; adds $9mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice